Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab

Bibliography

• Gasparini G, Longo R, Torino F, Therapy of breast cancer with molecular targeting agents. Ann Oncol 2005;16(Suppl 4):iv 28-36
   Google Scholar
• Ross JS, Slodkowska EA, Symmans WF, The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14(4):320-68
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Siminoff LA, Davis GJ, Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19(4):980-91
   PubMed Web of Science ®Google Scholar
• Liu R, Wang X, Chen GY, The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356(3):217-26
   PubMed Web of Science ®Google Scholar
• Massagué J. Sorting out breast-cancer gene signatures. N Engl J Med 2007;356(3):294-7
   PubMed Web of Science ®Google Scholar
• Acharya CR, Hsu DS, Anders CK, Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 2008;299(13):1574-87
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, Verweij J, De Jonge MJ, Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002;20:81-7
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B, Initial sequencing and analysis of the human genome. Nature 2001;409:860-921
   PubMed Web of Science ®Google Scholar
• Iyer L. Inherited variations in drug-metabolizing enzymes: significance in clinical oncology. Mol Diagn 1999;4:327-33
   PubMedGoogle Scholar
• Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667-71
   PubMed Web of Science ®Google Scholar
• Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for “Can't Predict Toxicity”? J Clin Oncol 2002;20:7-8
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae JM, Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64
   PubMed Web of Science ®Google Scholar
• Lim YC, Li L, Desta Z, Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-taoxifen induce similar patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 2006;318:503-12
   PubMed Web of Science ®Google Scholar
• Desta Z, Ward BA, Soukhova NV, Comprehensive evaluation of tamoxifen sequential biotransformations by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310:1062-75
   PubMed Web of Science ®Google Scholar
• Lim H-S, Lee HJ, Lee ES, Clinical implications of CYP2D6 gnotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007;25:3837-45
   PubMed Web of Science ®Google Scholar
• Tan SH, Lee SC, Goh BC, Pharmacogenetics in breast cancer therapy. Clin Cancer Res 2008;14:8027-41
   PubMed Web of Science ®Google Scholar
• Goetz MP, Rae JM, Suman VJ, Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-8
   PubMed Web of Science ®Google Scholar
• Schroth W, Antoniadou L, Fritz P, Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP 2C19 genotypes. J Clin Oncol 2007;25:5187-93
   PubMed Web of Science ®Google Scholar
• Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008;83:160-6
   PubMed Web of Science ®Google Scholar
• Schroth W, Goetz MP, Hamann U, Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302(13):1429-36
   PubMed Web of Science ®Google Scholar
• Goetz MP, Knox SK, Suman VJ, The impact of cytochrome P4502D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-21
   PubMed Web of Science ®Google Scholar
• Goetz MP, Suman V, Amesw M, Tamoxifen pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: long term follow-up of the North Central Cancer Treatment Group 89-30-52 adyuvant trial [abstract]. Cancer Res 2009;69(Suppl):6037
   Google Scholar
• Wegman P, Elingarami S, Carstensen J, Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B154 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007;9:R7
   PubMed Web of Science ®Google Scholar
• Wegman P, Vainikka L, Stal O, Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005;7:R284-90
   PubMed Web of Science ®Google Scholar
• Henry NL, Hayes DF. CYP2D6 testing for breast cancer patients: is there more to the story? Oncology 2009;23(14):77-8
   Google Scholar
• Borges S, Desta Z, Li L, Quantitative effect of CYP2D6 genotype and inhibitors of tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80:61-74
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. In: Kalow W, editor, Pharmacogenetics of drug metabolism. Pergamon Press, Inc., New York, NY; 1992. p. 625-48
   Google Scholar
• Jin Y, Desta Z, Stearns V, CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97(1):30-9
   PubMed Web of Science ®Google Scholar
• Aubert RE, Stanek EJ, Yao J, Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol 2009;27(18S): abstract CRA 508
   Google Scholar
• Dezentjé V, Van Blijderveen NJ, Gelderblom H, Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early–stage breast cancer: a pharmacoepidemiologic study. J Clin Oncol 2009;27(18S): abstract CRA509
   Google Scholar
• Holzman D. Tamoxifen antidepressants, and CYP2D6: the conundrum continues. J Natl Cancer Inst 2009;101:1370-1
   PubMed Web of Science ®Google Scholar
• Nowell S, Sweeney C, Winters M, Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 2002;94:1635-40
   PubMed Web of Science ®Google Scholar
• Nowell SA, Ahn J, Rae JM, Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-58
   PubMed Web of Science ®Google Scholar
• Ma CX, Adjei AA, Salvaggione OE, Human aromatase: gene resequencing and functional genomics. Cancer Res 2005;65:11071-82
   PubMed Web of Science ®Google Scholar
• Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 2006;45(3):235-52
   PubMed Web of Science ®Google Scholar
• Puisset F, Chatelut E, Dalenc F, Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 2004;54(3):265-72
   PubMed Web of Science ®Google Scholar
• Hirth J, Watkins PB, Strawderman M, The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000;6(4):1255-8
   PubMed Web of Science ®Google Scholar
• Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10(3):187-216
   PubMedGoogle Scholar
• Yamamoto N, Tamura T, Kamiya Y, Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000;18(11):2301-8
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Tamura T, Murakami H, Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005;23(6):1061-9
   PubMed Web of Science ®Google Scholar
• Hor SY, Lee SC, Wong CI, PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J 2008;8(2):139-46
   PubMed Web of Science ®Google Scholar
• Lewis LD, Miller AA, Rosner GL, A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 2007;13(11):3302-11
   PubMed Web of Science ®Google Scholar
• Smith NF, Acharya MR, Desai N, Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005;4(8):815-8
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Ouwehand M, Buckle T, Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62(21):6158-64
   PubMed Web of Science ®Google Scholar
• Huisman MT, Chhatta AA, van Tellingen O, MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005;116(5):824-9
   PubMed Web of Science ®Google Scholar
• Iwao-Koizumi K, Matoba R, Ueno N, Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005;23(3):422-31
   PubMed Web of Science ®Google Scholar
• Bosch TM, Huitema AD, Doodeman VD, Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006;12(19):5786-93
   PubMed Web of Science ®Google Scholar
• Tran A, Jullien V, Alexandre J, Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79(6):570-80
   PubMed Web of Science ®Google Scholar
• Baker SD, Verweij J, Cusatis GA, Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009;85(2):155-63
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Danesi R, Ando Y, Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Update 2003;6(2):71-84
   PubMed Web of Science ®Google Scholar
• Marsh S, Somlo G, Li X, Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 2007;7(5):362-5
   PubMed Web of Science ®Google Scholar
• Nakajima M, Fujiki Y, Kyo S, Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 2005;45(6):674-82
   PubMed Web of Science ®Google Scholar
• Gréen H, Söderkvist P, Rosenberg P, mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006;12(3 Pt 1):854-9
   PubMed Web of Science ®Google Scholar
• Johnatty SE, Beesley J, Paul J, ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 2008;14(17):5594-601
   PubMed Web of Science ®Google Scholar
• Marsh S, Paul J, King CR, Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007;25(29):4528-35
   PubMed Web of Science ®Google Scholar
• Sissung TM, Danesi R, Price DK, Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 2008;7(1):19-26
   PubMed Web of Science ®Google Scholar
• Marsh S. Taxane pharmacogenetics. Personalized Med 2006;3:33-43
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX, Lofgren JA, Lewis GD, Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6
   PubMed Web of Science ®Google Scholar
• Carson WE, Parihar R, Lindemann MJ, Interleukin-2 enhances the natural killer cell response to Herceptin-coated HER-2/neu–positive breast cancer cells. Eur J Immunol 2001;31:3016-25
   PubMed Web of Science ®Google Scholar
• Gennari R, Menard S, Fagnoni F, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-5
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F, Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259-67
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Ritz J. Biology and relevance of human natural killer cells. Blood 1990;76:2421-38
   PubMed Web of Science ®Google Scholar
• Koene HR, Kleijer M, Algra J, Fc-gamma-RIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc-gamma-RIIIa, independently of the Fc-gamma-RIIIa-48 L/R/H phenotype. Blood 1997;90:1109-14
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, High resolution mapping of the binding site on human IgG1 for FcRI, FcRII, FcRIII, and FcRn and design of IgG1 variants with improves binding to the FcR. J Biol Chem 2001;9:6591-604
   Google Scholar
• Warmerdam PA, van de Winkel JGJ, Vlug A, A single amino acid in the second Ig-like domain of the human Fc receptor II is critical for human IgG2 binding. J Immunol 1991;147:1338-43
   PubMed Web of Science ®Google Scholar
• Weng W-K, Levy R. Two immunoglobulin G fragment receptors polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7
   PubMed Web of Science ®Google Scholar
• Musolino A, Naldi N, Bortesi B, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26(11):1789-96
   PubMed Web of Science ®Google Scholar
• Zhang W, Gordon M, Schultheis AM, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-8
   PubMed Web of Science ®Google Scholar
• Gennari R, Menard S, Fagnoni F, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-5
   PubMed Web of Science ®Google Scholar
• Varchetta S, Gibelli N, Oliviero B, Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007;67:11991-9
   PubMed Web of Science ®Google Scholar
• Jubb AM, Hurwitz HI, Bai W, Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24:217-27
   PubMed Web of Science ®Google Scholar
• Longo R, Gasparini G. Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev Mol Diagn 2008;8(3):301-14
   PubMed Web of Science ®Google Scholar
• Stevens A, Soden J, Brenchley PE, Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003;63:812-6
   PubMed Web of Science ®Google Scholar
• Schneider BP, Radovich M, Sledge GW, Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 2008;111(1):157-63
   PubMed Web of Science ®Google Scholar
• Krippl P, Langsenlehner U, Renner W, A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003;106:468-71
   PubMed Web of Science ®Google Scholar
• Jacobs EJ, Feigelson HS, Bain EB, Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 2006;8:R22
   PubMed Web of Science ®Google Scholar
• Jin Q, Hemminki K, Enquist K, Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 2005;11:3647-53
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radovich M, Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26(28):4672-8
   PubMed Web of Science ®Google Scholar
• Schultheis AM, Lurje G, Rhodes KE, Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008;14(22):7554-63
   PubMed Web of Science ®Google Scholar